Evolution of WHO diagnostic criteria in “Classical Myeloproliferative Neoplasms” compared with the International Consensus Classification

IF 11.6 1区 医学 Q1 HEMATOLOGY
Jürgen Thiele, Hans Michael Kvasnicka, Umberto Gianelli, Daniel A. Arber, Ayalew Tefferi, Alessandro M. Vannucchi, Tiziano Barbui, Attilio Orazi
{"title":"Evolution of WHO diagnostic criteria in “Classical Myeloproliferative Neoplasms” compared with the International Consensus Classification","authors":"Jürgen Thiele, Hans Michael Kvasnicka, Umberto Gianelli, Daniel A. Arber, Ayalew Tefferi, Alessandro M. Vannucchi, Tiziano Barbui, Attilio Orazi","doi":"10.1038/s41408-025-01235-7","DOIUrl":null,"url":null,"abstract":"<p>A lively discussion persists regarding the diagnostic criteria for essential thrombocythemia (ET), primary myelofibrosis (PMF) and polycythemia vera (PV), particularly in relation to early/pre-fibrotic myelofibrosis (pre-PMF), a disease entity initially introduced in 2001 by the 3<sup>rd</sup> edition of the World Health Organization (WHO) classification. The definition and criteria used to diagnose pre-PMF have been progressively modified over time. The most update definition of pre-PMF can be found in the International Consensus Classification (ICC) published in 2022. An updated largely similar definition is also incorporated in the recently published 5<sup>th</sup> edition of WHO classification (2024). Diagnostic criteria for ET have undergone changes up to 2016/17 for the revised 4<sup>th</sup> edition of the WHO. In particular the threshold value for platelets were lowered and the important discrimination between “true” and “false” ET (in reality pre-PMF) been widely acknowledged. To avoid misdiagnose in early phase PV, the criteria for gender-adjusted thresholds for hemoglobin/ hematocrit have been lowered and the identification of an appropriate bone marrow (BM) morphology was upgraded as a major diagnostic criterion. Given the prominent role of morphology in MPN-related diagnostic algorithms, the diagnostic adequacy of the BM biopsy (sample procurement and proper laboratory handling) as emphasized in former WHO editions and in the ICC, was not addressed by the WHO 5<sup>th</sup>. The essential role of genetic markers is recognized by both classifications. A comparison between the revised 4<sup>th</sup> edition WHO classification and the ICC versus the WHO 5<sup>th</sup> reveals no significant differences, with the exception of the occurrence of leukoerythroblastosis in pre-PMF considered by the latter as one of the minor diagnostic criteria which seems unwarranted. In contrast to the revised 4<sup>th</sup> edition, the majority of the microscopic images used for the WHO 5<sup>th</sup> due to their low magnification and poor technique, do not highlight the diagnosis differences among these entities.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"36 1","pages":""},"PeriodicalIF":11.6000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41408-025-01235-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

A lively discussion persists regarding the diagnostic criteria for essential thrombocythemia (ET), primary myelofibrosis (PMF) and polycythemia vera (PV), particularly in relation to early/pre-fibrotic myelofibrosis (pre-PMF), a disease entity initially introduced in 2001 by the 3rd edition of the World Health Organization (WHO) classification. The definition and criteria used to diagnose pre-PMF have been progressively modified over time. The most update definition of pre-PMF can be found in the International Consensus Classification (ICC) published in 2022. An updated largely similar definition is also incorporated in the recently published 5th edition of WHO classification (2024). Diagnostic criteria for ET have undergone changes up to 2016/17 for the revised 4th edition of the WHO. In particular the threshold value for platelets were lowered and the important discrimination between “true” and “false” ET (in reality pre-PMF) been widely acknowledged. To avoid misdiagnose in early phase PV, the criteria for gender-adjusted thresholds for hemoglobin/ hematocrit have been lowered and the identification of an appropriate bone marrow (BM) morphology was upgraded as a major diagnostic criterion. Given the prominent role of morphology in MPN-related diagnostic algorithms, the diagnostic adequacy of the BM biopsy (sample procurement and proper laboratory handling) as emphasized in former WHO editions and in the ICC, was not addressed by the WHO 5th. The essential role of genetic markers is recognized by both classifications. A comparison between the revised 4th edition WHO classification and the ICC versus the WHO 5th reveals no significant differences, with the exception of the occurrence of leukoerythroblastosis in pre-PMF considered by the latter as one of the minor diagnostic criteria which seems unwarranted. In contrast to the revised 4th edition, the majority of the microscopic images used for the WHO 5th due to their low magnification and poor technique, do not highlight the diagnosis differences among these entities.

WHO“经典骨髓增生性肿瘤”诊断标准与国际共识分类的比较
关于原发性血小板增多症(ET)、原发性骨髓纤维化(PMF)和真性红细胞增多症(PV)的诊断标准,特别是与早期/纤维化前骨髓纤维化(pre-PMF)有关的诊断标准,一直存在热烈的讨论,这是2001年世界卫生组织(WHO)分类第三版首次引入的一种疾病实体。随着时间的推移,用于诊断pmf前期的定义和标准已逐步修改。预pmf的最新定义可在2022年出版的《国际共识分类》中找到。最近出版的世卫组织第五版分类(2024年)中也纳入了一个更新后的大致相似的定义。截至2016/17年,经修订的世卫组织第四版ET诊断标准发生了变化。特别是血小板的阈值被降低,“真”和“假”ET(实际上是pmf前)之间的重要区别被广泛承认。为了避免早期PV的误诊,降低了性别调整的血红蛋白/红细胞压积阈值的标准,并将鉴定合适的骨髓(BM)形态学升级为主要诊断标准。鉴于形态学在mpn相关诊断算法中的突出作用,世卫组织以前的版本和ICC中强调的BM活检诊断的充分性(样本采购和适当的实验室处理)在世卫组织第5次会议中没有得到解决。两种分类都认识到遗传标记的重要作用。经修订的世卫组织第4版分类和ICC与世卫组织第5版分类的比较显示,除了在pmf前出现成白细胞增多症被后者视为次要诊断标准之一,这似乎是没有根据的,没有显著差异。与修订后的第4版相比,世卫组织第5版使用的大多数显微图像由于其低放大倍率和较差的技术,没有突出这些实体之间的诊断差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
16.70
自引率
2.30%
发文量
153
审稿时长
>12 weeks
期刊介绍: Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as: Preclinical studies of new compounds, especially those that provide mechanistic insights Clinical trials and observations Reviews related to new drugs and current management of hematologic malignancies Novel observations related to new mutations, molecular pathways, and tumor genomics Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信